Abstract Background and Objectives New treatments and interventions are in development
to address clinical needs in heart failure. To support decision making on reimbursement …

Importance In the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure
(DAPA-HF) trial, dapagliflozin was shown to reduce cardiovascular mortality and …

Background Under usual care, people with an implantable cardioverter-defibrillator (ICD),
cardiac resynchronization therapy with or without a defibrillator (CRT-D and CRT-P …

Importance In the Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With
Preserved Ejection Fraction (EMPEROR-Preserved), empagliflozin significantly reduced …

Aims Exploratory assessment of the potential benefits of the novel soluble guanylate cyclase
stimulator vericiguat on health status in patients with heart failure (HF) with preserved …

Objective Chronic heart failure with reduced ejection fraction (HF-REF) represents a major
public health issue and is associated with considerable morbidity and mortality. We …

Aims Heart failure (HF) treatment guided by physicians with access to real‐time pressure
measurement from a wireless implantable pulmonary artery pressure (PAP) sensor …

Aims Previous cost‐effectiveness analysis suggests that CardioMEMS is cost‐effective
compared with usual care for patients with persistent New York Heart Association class III …

Background Heart failure (HF) is a multifaceted syndrome that requires self-management for
adherence to treatment to control symptoms. Symptoms need to be monitored to prevent …

Background: Telerehabilitation in the Heart Failure Patients (TELEREH-HF) study showed a
statistically significant improvement in the tertiary outcomes ie the New York Heart …